Literature DB >> 9149944

Fine localization of the torsion dystonia gene (DYT1) on human chromosome 9q34: YAC map and linkage disequilibrium.

L J Ozelius1, J Hewett, P Kramer, S B Bressman, C Shalish, D de Leon, M Rutter, N Risch, M F Brin, E D Markova, S A Limborska, I A Ivanova-Smolenskaya, M K McCormick, S Fahn, A J Buckler, J F Gusella, X O Breakefield.   

Abstract

The DYT1 gene, which maps to chromosome 9q34, appears to be responsible for most cases of early-onset torsion dystonia in both Ashkenazic Jewish (AJ) and non-Jewish families. This disease is inherited in an autosomal dominant mode with reduced penetrance (30%-40%). The abnormal involuntary movements associated with this disease are believed to be caused by unbalanced neural transmission in the basal ganglia. Previous linkage disequilibrium studies in the AJ population placed the DYT1 gene in a 2-cM region between the loci D9S62a and ASS. A YAC contig has now been created spanning 600 kb of this region including D9S62a. The location of the DYT1 gene has been refined within this contig using several new polymorphic loci to expand the linkage disequilibrium analysis of the AJ founder mutation. The most likely location of the DYT1 gene is within a 150 kb region between the loci D9S2161 and D9S63.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9149944     DOI: 10.1101/gr.7.5.483

Source DB:  PubMed          Journal:  Genome Res        ISSN: 1088-9051            Impact factor:   9.043


  11 in total

1.  Deep-Brain Stimulation for Basal Ganglia Disorders.

Authors:  Thomas Wichmann; Mahlon R Delong
Journal:  Basal Ganglia       Date:  2011-07-01

2.  Dysregulation of striatal dopamine release in a mouse model of dystonia.

Authors:  Li Bao; Jyoti C Patel; Ruth H Walker; Pullanipally Shashidharan; Margaret E Rice
Journal:  J Neurochem       Date:  2010-07-27       Impact factor: 5.372

Review 3.  Recent advances in RNA interference therapeutics for CNS diseases.

Authors:  Pavitra S Ramachandran; Megan S Keiser; Beverly L Davidson
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

4.  Precise genetic mapping and haplotype analysis of the familial dysautonomia gene on human chromosome 9q31.

Authors:  A Blumenfeld; S A Slaugenhaupt; C B Liebert; V Temper; C Maayan; S Gill; D E Lucente; M Idelson; K MacCormack; M A Monahan; J Mull; M Leyne; M Mendillo; T Schiripo; E Mishori; X Breakefield; F B Axelrod; J F Gusella
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

Review 5.  Deep Brain Stimulation for Movement Disorders of Basal Ganglia Origin: Restoring Function or Functionality?

Authors:  Thomas Wichmann; Mahlon R DeLong
Journal:  Neurotherapeutics       Date:  2016-04       Impact factor: 7.620

Review 6.  The treatment of movement disorders by deep brain stimulation.

Authors:  Hong Yu; Joseph S Neimat
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

7.  Cortically evoked long-lasting inhibition of pallidal neurons in a transgenic mouse model of dystonia.

Authors:  Satomi Chiken; Pullanipally Shashidharan; Atsushi Nambu
Journal:  J Neurosci       Date:  2008-12-17       Impact factor: 6.167

8.  Is the early-onset torsion dystonia (EOTD) linked to TOR1A gene as frequent as expected in France?

Authors:  M Y Frédéric; F Clot; L Cif; A Blanchard; A Dürr; I Vuillaume; G Lesca; A Kreisler; C Davin; T Besnard; F Rousset; D Thorel; C Saquet; D Mechin; L Ozelius; Y Agid; B Barroso; B Chabrol; V Chan; M Clanet; C Coubes; A Destee; K Nguyen; C Vial; M Vidailhet; J Xie; B Sablonniere; A Calender; A Brice; A Roubertie; P Coubes; M Claustres; S Tuffery-Giraud; G Collod-Beroud
Journal:  Neurogenetics       Date:  2008-03-06       Impact factor: 2.660

9.  Intragenic Cis and Trans modification of genetic susceptibility in DYT1 torsion dystonia.

Authors:  Neil J Risch; Susan B Bressman; Geetha Senthil; Laurie J Ozelius
Journal:  Am J Hum Genet       Date:  2007-04-27       Impact factor: 11.025

Review 10.  Deep brain stimulation for movement disorders.

Authors:  Paul S Larson
Journal:  Neurotherapeutics       Date:  2014-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.